Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | ICMT | O60725 | 16/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27728281 | 0.81 | TSHR (0.54) | TSHRICMTGAAMEN1KMT2A | |
| SCHEMBL10956561 | 0.80 | TSHR (0.41) | TSHRICMTGAAMEN1KMT2A | |
| SCHEMBL343450 | 0.75 | ALDH1A1 (0.45) | TSHRICMT | |
| SCHEMBL13546073 | 0.75 | TSHR (0.49) | TSHRICMTGAAMEN1KMT2A | |
| SCHEMBL19381874 | 0.72 | ALDH1A1 (0.39) | TSHRICMT | |
| SCHEMBL13546083 | 0.72 | ICMT (0.67) | TSHRICMTMEN1KMT2A | |
| SCHEMBL6439975 | 0.71 | OPRL1 (0.44) | GAAMEN1KMT2A | |
| SCHEMBL6439973 | 0.71 | OPRL1 (0.44) | GAAMEN1KMT2A | |
| SCHEMBL498014 | 0.71 | OPRM1 (0.50) | GAAMEN1KMT2A | |
| SCHEMBL18778704 | 0.71 | POLB (0.41) | TSHRICMTGAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993561-B2 | Nitrobenzothiazole derivatives, preparation thereof and therapeutic applications thereof | SANOFI (FR) | 2015-03-31 | — | — | US | disclosed |
| US-8993561-B2 | Nitrobenzothiazole derivatives, preparation thereof and therapeutic applications thereof | SANOFI (FR) | 2015-03-31 | — | — | US | disclosed |
| EP-2643307-B1 | NITROBENZOTHIAZOLE DERIVATIVES AND USE THEREOF FOR TREATING TUBERCULOSIS | SANOFI SA (FR) | 2014-09-17 | — | — | EP | disclosed |
| US-20130245008-A1 | NITROBENZOTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATIONS THEREOF | SANOFI (FR) | 2013-09-19 | — | — | US | disclosed |
| US-20130245008-A1 | NITROBENZOTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATIONS THEREOF | SANOFI (FR) | 2013-09-19 | — | — | US | disclosed |
| WO-2012069743-A1 | NITROBENZOTHIAZOLE DERIVATIVES AND USE THEREOF FOR TREATING TUBERCULOSIS | SANOFI (FR) | 2012-05-31 | — | — | WO | disclosed |
| US-20100022637-A1 | IDENTIFICATION OF ANTI-CANCER COMPOUNDS AND COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE AND METHODS OF TREATMENT THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100022637-A1 | IDENTIFICATION OF ANTI-CANCER COMPOUNDS AND COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE AND METHODS OF TREATMENT THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245008-A1 | NITROBENZOTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATIONS THEREOF | NDUFB7, NDUFB3, SDHB | TSHR 1511/4885ICMT 472/4885GAA 410/4885 |
| US-20100022637-A1 | IDENTIFICATION OF ANTI-CANCER COMPOUNDS AND COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE AND METHODS OF TREATMENT THEREOF | HTT, ATXN2, HDAC6 | TSHR 3934/4885ICMT 2904/4885GAA 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.